Latest:
Treatment Trends and Ongoing Research in Pediatric Acute Leukemia
Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kaveh Zakeri, MD, MAS
Latest:
Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck Cancers
A personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.
Matthew Lee, MD
Matthew Lee, MD, is an assistant professor in the Department of Medical Oncology and Therapeutics Research at the City of Hope in Duarte, California.
Latest:
Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC
Matthew Lee, MD, details the improved disease-free survival outcomes with adjuvant alectinib in patients with ALK-positive NSCLC.
Bruce Brockstein, MD
Latest:
RP1: An Emerging Intratumoral Therapy
Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.
Megan Hitchins, PhD
Latest:
Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers
Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.
Onyee Chan, MD
Latest:
Clinical Perspectives: A 45-Year-Old Man With R/R CML
Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.
Fadi Haddad, MD
Fadi Haddad, MD, is an assistant professor and co-leader of the Section of Chronic Myeloid Leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Latest:
Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML
Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.
Tashanna K. Myers, MD
Tashanna K. Myers, MD, is a professor of obstetrics and gynecology at the UMass Chan Medical School—Baystate
Latest:
Dr Myers on Mitigation Strategies for Ocular AEs in Platinum-Resistant Ovarian Cancer
Tashanna K. Myers, MD, discusses the importance of telling patients with ovarian cancer about the HRQOL outcomes associated with mirvetuximab soravtansine.